Program
trifluridine tipiracil drug combination
Also written as “TAS-102”, “Trifluridine/Tipiracil” and “Trifluridine and Tipiracil Tablets”.
Its studies are mostly in Colorectal Neoplasms · Breast Neoplasms · Liver Neoplasms · Kidney Diseases · Small Cell Lung Carcinoma, led by 11 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Otsukaits history only | 130 open or running | phase 3since May 24, 2012 | May 24, 2012 | none ahead |
| Sino Biopharmaceuticalits history only | 32 open or running | phase 3since Mar 6, 2026 | May 31, 2019 | Aug 2027phase 3 · NCT07483684 |
| AbbVieits history only | 11 open or running | phase 3since Apr 7, 2026 | Apr 7, 2026 | May 2029phase 3 · NCT07525206 |
| Criteriumits history only | 11 open or running | phase 2since Apr 30, 2025 | Apr 30, 2025 | Dec 31, 2027phase 2 · NCT06992258 |
| Elevar Therapeuticsits history only | 10 open or running | phase 1since Aug 26, 2019 | Aug 26, 2019 | none ahead |
| GamaMabs Pharmaits history only | 10 open or running | phase 2since Jan 8, 2019 | Jan 8, 2019 | none ahead |
| Gilead Sciences | 11 open or running | phase 2since Apr 7, 2026 | Apr 7, 2026 | Dec 2028phase 2 · NCT07527858 |
| Jiangsu HengRui Medicineits history only | 11 open or running | phase 3since Dec 26, 2023 | Dec 26, 2023 | none ahead |
| Lunan Pharmaceutical Groupits history only | 10 open or running | no phasesince Mar 19, 2026 | Mar 19, 2026 | none ahead |
| STCubeits history only | 11 open or running | phase 1since May 27, 2026 | May 27, 2026 | Jul 31, 2028phase 1 · NCT07656038 |
| Takedaits history only | 10 open or running | phase 2since Nov 20, 2015 | Nov 20, 2015 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Gilead Sciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 7, 2026First study: phase 2 study in Advanced Microsatellite Stable Colorectal CancerFirst studyNCT07527858 · 170 planned · United States, Australia, South Korea and more
Ahead
- Dec 2028Primary completion: phase 2 study in Advanced Microsatellite Stable Colorectal CancerNCT07527858
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Gilead Sciences leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07527858Advanced Microsatellite Stable Colorectal Cancer · United States, Australia, South Korea and more | 2 | Recruiting | Dec 2028 | 170 |
How it is read
Names in the registry
- “TAS-102”, 11 entries
- “Trifluridine/Tipiracil”, 3 entries
- “Trifluridine and Tipiracil Tablets”, 2 entries
- “Trifluridine-Tipiracil”, 1 entry
- “Fruquintinib+ Lonsurf (trifluridine and tipiracil)”, 1 entry
Codes read as this program: TAS102.
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 13 studies
- Breast Neoplasms, 2 studies
- Liver Neoplasms, 1 study
- Kidney Diseases, 1 study
- Small Cell Lung Carcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.